Aktienanalyse zu Acurx Pharmaceuticals Inc (ACXP)ACXPAcurx Pharmaceuticals Inc

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Acurx Pharmaceuticals Inc (ACXP) is a good buy right now due to its recent positive developments, including a conditional FDA acceptance for its antibiotic candidate CIFBEZY and an improved cash position of $10.7 million, which supports operational funding for at least one year. The stock is currently priced at $1.065, significantly below its 52-week high of $7.54, indicating a potential for recovery. However, investors should be cautious of the company's ongoing net losses, which amounted to $2.3 million in Q2 2026, as this represents a risk to profitability.